Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/31/2002WO2002085899A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002WO2002085898A1 Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
10/31/2002WO2002085897A1 Heterocyclic compounds for aging-related and diabetic vascular complications
10/31/2002WO2002085895A1 Quinazoline derivatives
10/31/2002WO2002085894A1 Arylindenopyridines with pde inhibiting activity
10/31/2002WO2002085892A1 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
10/31/2002WO2002085891A1 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
10/31/2002WO2002085889A1 Crystalline form of omeprazole
10/31/2002WO2002085888A1 Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same
10/31/2002WO2002085887A1 Phenyl- and pyridyl-piperidines with tnf activity
10/31/2002WO2002085886A2 Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
10/31/2002WO2002085885A1 Piperazino-derivatives and their use as pde4 inhibitor
10/31/2002WO2002085883A1 Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
10/31/2002WO2002085882A1 Coumarin derivatives to be used as anticoagulants
10/31/2002WO2002085879A1 Three-step conversion of protected taxane ester to paclitaxel
10/31/2002WO2002085878A1 Two-step conversion of protected taxane ester to paclitaxel
10/31/2002WO2002085870A1 Novel azoles having an insecticidal action
10/31/2002WO2002085869A1 Arylsulfonamides as antiviral agents
10/31/2002WO2002085868A1 Benzoxazinone derivatives for use in the treatment of angiogenesis
10/31/2002WO2002085866A1 Novel compounds
10/31/2002WO2002085865A1 A method for the preparation of oxazolidinones
10/31/2002WO2002085864A1 Compounds of the family of 3-alkyl-(4,5 dipheny-imidazol-1-yl) and their use as soothing agents
10/31/2002WO2002085863A1 Novel compounds of the family of 3-alkyl-(4,5 diphenyl-imidazol-1-yl) and their use as soothing agents
10/31/2002WO2002085860A1 Pyrazole derivatives for treating hiv
10/31/2002WO2002085859A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
10/31/2002WO2002085857A2 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
10/31/2002WO2002085855A1 2-iminopyrrolidine derivatives
10/31/2002WO2002085853A2 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
10/31/2002WO2002085850A1 Cyclic amidine derivative
10/31/2002WO2002085844A1 New compounds
10/31/2002WO2002085843A2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
10/31/2002WO2002085839A1 Fused bicyclic or tricyclic amino acids
10/31/2002WO2002085827A1 Extract from the pods of lupin seeds containing lupeol
10/31/2002WO2002085789A2 Magnesium di-pot assium edta complex and method of administration
10/31/2002WO2002085459A2 Antiangiogenic combination therapy for the treatment of cancer
10/31/2002WO2002085458A2 Use of nk-1 receptor antagonists against benign prostatic hyperplasia
10/31/2002WO2002085447A2 Microprojection array having a beneficial agent containing coating
10/31/2002WO2002085434A1 Injection device for administering rna
10/31/2002WO2002085414A2 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
10/31/2002WO2002085413A1 Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same
10/31/2002WO2002085412A1 Tissue fibrosis inhibitors
10/31/2002WO2002085410A2 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls
10/31/2002WO2002085403A1 Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5
10/31/2002WO2002085402A1 Methods and compositions for treating oral and eosophageal lesions
10/31/2002WO2002085400A1 Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase
10/31/2002WO2002085398A1 Lithospermic acid-containing composition
10/31/2002WO2002085395A1 Total glycosides of paeony, method to prepare the same and uses thereof
10/31/2002WO2002085393A1 Hop extracts and use thereof in the production of a medicament having estrogenic properties
10/31/2002WO2002085392A1 Method for using puerariae radix, puerariae radix flavone extract and preparation containing puerarin in the prevention and treatment of new indications
10/31/2002WO2002085390A1 Composition and method for the prevention and treatment of acne
10/31/2002WO2002085383A1 Method for reducing copper levels and treating copper toxicosis
10/31/2002WO2002085382A1 Methods of treating syndrome x with aliphatic polyamines
10/31/2002WO2002085381A1 Method for treating gout and binding uric acid
10/31/2002WO2002085380A1 Method for treating gout and reducing serum uric acid
10/31/2002WO2002085379A1 Method for improving vascular access in patients with vascular shunts
10/31/2002WO2002085378A1 Low salt forms of polyallylamine
10/31/2002WO2002085377A1 Method for lowering serum glucose
10/31/2002WO2002085376A2 A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress
10/31/2002WO2002085375A1 Novel hormone composition
10/31/2002WO2002085374A1 Estriol therapy for multiple sclerosis and other autoimmune diseases
10/31/2002WO2002085373A1 Composition and methods for treatment of asthma symptoms and reducing adenosine/adenosine receptor levels
10/31/2002WO2002085372A1 Medicines and medicinal kits
10/31/2002WO2002085371A1 Noninvasive method for treating cellulite through transdermal delivery of calcium channel blocker agents and medicament for use in such method
10/31/2002WO2002085370A1 Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances
10/31/2002WO2002085369A1 Inhibitors of anthrax lethal factor activity
10/31/2002WO2002085368A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002WO2002085367A1 Methods of treatment using an epithelial sodium channel blocker and an inhibitor of the mineralocorticoid receptor
10/31/2002WO2002085366A1 Aripiprazole oral solution
10/31/2002WO2002085365A1 Tricyclic compounds useful as hiv reverse transcriptase inhibitors
10/31/2002WO2002085364A1 Farnesyl protein transferase inhibitors for treating cachexia
10/31/2002WO2002085363A1 Remedial agent for glomerular disease
10/31/2002WO2002085362A2 Dermatological composition comprising nicotinic acid or an amide, and a sphingoid base
10/31/2002WO2002085361A1 Benzimidazolone compounds
10/31/2002WO2002085359A1 Agent for topical ophthalmic treatment of ocular inflammatory diseases
10/31/2002WO2002085358A2 Antiviral agents and methods of treating viral infections
10/31/2002WO2002085357A1 Nociceptin analogs
10/31/2002WO2002085355A1 Spiropyrazole compounds
10/31/2002WO2002085354A1 Spiroindene and spiroindane compounds
10/31/2002WO2002085352A1 Nmda-antagonists and nmda-agonists for the treatment of addictive illnesses
10/31/2002WO2002085351A1 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
10/31/2002WO2002085350A1 Prodigiosin composition for the treatment of rheumatic arthritis
10/31/2002WO2002085349A1 Use of active substance combinations from alpha lipoic acid and substances that absorb light in the uv-a and/or uv-b range for use in the treatment and/or prophylaxis of undesired cutaneous pigmentation
10/31/2002WO2002085348A1 Use of rare earth compounds for the prevention of kidney stone disease
10/31/2002WO2002085347A1 Preventive/remedial agent for inflammatory disease in oral-cavity mucosa and the like
10/31/2002WO2002085346A1 Use of creatine for the amelioration of oxidative stress
10/31/2002WO2002085345A1 Method of preventing or treating breast, prostate and/or cervical cancer with n,n-dimethylglycine
10/31/2002WO2002085344A1 Noninvasive methods for treating hemangiomas
10/31/2002WO2002085343A1 Thrombopoietin mimetics
10/31/2002WO2002085342A2 Use of nsaids for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
10/31/2002WO2002085341A2 Composition, containing carnitine and huperzin for the preventionor treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
10/31/2002WO2002085340A2 Oligonucleotide compositions and their use to induce differentiation of cells
10/31/2002WO2002085338A2 Ipratropium formulation for pulmonary inhalation
10/31/2002WO2002085337A1 Micellar drug delivery systems for hydrophobic drugs
10/31/2002WO2002085335A1 A novel coating for a sustained release pharmaceutical composition
10/31/2002WO2002085331A1 Fast disintegrating meloxicam tablet
10/31/2002WO2002085330A1 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
10/31/2002WO2002085328A2 Method for producing an active ingredient concentrate, and an active ingredient concentrate
10/31/2002WO2002085327A2 Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
10/31/2002WO2002085322A1 Skin-protective compositions effective against vesicants and percutaneous chemical agents
10/31/2002WO2002085312A2 Process for purifying 6-methoxy omeprazole
1 ... 5662 5663 5664 5665 5666 5667 5668 5669 5670 5671 5672 5673 5674 5675 5676 5677 5678 5679 5680 5681 5682 ... 7860